Sun Pharma forays into Japan with $293 million product buy from Novartis

pharmafile | March 30, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing Japan, M&A, MA, Novartis, Sun Pharma, generics 

Shares of Sun Pharma (BOM: 524715), the largest Indian drug maker rose over 2% Wednesday as the company announced the acquisition of 14 brands in Japan from Swiss pharma major Novartis (VTX: NOVN) for $293 million.   

Under the terms of the deal, Novartis will continue to distribute these brands, for a certain period, pending transfer of all marketing authorizations to Sun Pharma.

Novartis brands had combined annualized revenues of about $160 million and address medical conditions across several therapeutic areas, the company said in a statement.

Sun Pharma’s managing director, Dilip Shanghvi, says: “Japan is a market of strategic interest for us. This acquisition marks Sun Pharma’s foray into the Japanese prescription market and provides us an opportunity to build a larger product portfolio in the future.” 

The Japanese pharmaceutical market is estimated to be worth $73 billion, accounting for over 7% of the $1 trillion global pharmaceutical market.

Shares in the company were trading up over 2% at 810.50 rupees on the Bombay Stock Exchange Wednesday. 

Anjali Shukla

Related Content

Sun Pharma and Pharmazz enter license agreement for Tyvalzi in India

Sun Pharma has announced that one of its wholly owned subsidiaries has entered into a …

Ionis and Novartis partner for CVD treatment programme

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement …


Novartis acquires Chinook Therapeutics for $3.5bn

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …

Latest content